About Rezulin (troglitazone); discontinued drug designed to treat type-2 diabetics

About Rezulin

What is Rezulin?: A prescription medication designed to treat type 2 diabetes, rezulin was known to pose serious health risks even before its release. Learn more about rezulin.
Risk Factors: What are the risks of rezulin? Are you at risk from rezulin? Read more about rezulin's risks.

Rezulin News Timeline

1997: January - Rezulin is approved by the FDA to treat Type II diabetes.; November - The FDA issues a warning about Rezulin (troglitazone). Recommended prescribing information is changed by the drug's manufacturer; new warning label information is added.; December - Approximately 150 adverse events associated with Rezulin have been reported to the FDA.
1998: June - The FDA and Rezulin manufacturer Parke-Davis agree to again tighten restrictions on the use of Rezulin.; July - Parke-Davis sends a letter to heathcare professionals warning to test for liver abnormalities and updating them on the changes in recommended use.
2001: March - Resulin sales are discontinued.

Contact Us

This information © 2002-2010 by the Drug Exposure Lawyers at Goldberg, Persky, & White, P.C. The content of this web site was developed as a service to mesothelioma patients and their families. Web site content has not been prepared or endorsed by physicians or licensed medical professionals. Nothing on this site should be taken as medical advice. Our staff are not physicians nor trained medical professionals and nothing they say should be taken as medical advice. The purpose of this site is to provide patients and their families with useful information and access to resources which may be helpful. Patients are encouraged to consult with their physician for medical advice and with an mesothelioma attorney for legal advice.

Last Updated: May 11, 2010. 11:08:28 am.